EU/3/18/2061

About

On 24 August 2018, orphan designation (EU/3/18/2061) was granted by the European Commission to Pharma Gateway AB, Sweden, for autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor for the treatment of glioma.

Key facts

Active substance
autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor
Disease / condition
Treatment of glioma
Date of first decision
24/08/2018
Outcome
Positive
EU designation number
EU/3/18/2061

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pharma Gateway AB
Johanneslundsvägen 2
194 81 Upplands Väsby
Sweden
Tel. +46 8 590 778 00
E-mail: info@pharmagateway.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating